A Phase 1b clinical study of GT-2108 in patients with moderate-to-severe Ulcerative Colitis

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Aug 2024 According to a Palisade Bio media release, the company has completed microbiome study, nonclinical IND/CTA-enabling studies, first Good Manufacturing Practice (GMP) batch. The company expects to complete analysis of ongoing IND/CTA-enabling tox studies by the end of the third quarter 2024, submit initial IND/CTA prior to the end of the third quarter of 2024. Initiate Phase 1a with UC patient cohort prior to the end of 2024.
08 Aug 2024 According to a Palisade Bio media release, based on the modeling and simulations, Palisade has established dose levels and trial design for PALI-2108.
29 Jul 2024 According to a Palisade Bio media release, expected to be initiated before the end of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com